Snake venoms are a rich source of bioactive molecules with diverse pharmacological activities. The potency and selectivity of these compounds hold great promise for drug discovery, with recent studies highlighting their potential as novel anticancer therapies.
Exciting private partnership
In this exciting project, researchers Jeroen Kool, Mátyás Bittenbinder and Julien Slagboom from the Vrije Universiteit’s Venom Research Group will partner with the organ-on-a-chip company MIMETAS to develop and utilize advanced organ-on-a-chip models for profiling snake venom toxins as potential anticancer drug candidates.
Go-to-contact for public-private partnerships at VU
Paul de Vries, from IXA-GO, helped the project in the partnering and proposal preparation process If you are interested in any future opportunities within ChemistryNL, or some of the other Topsectoren, feel free to reach out to Paul de Vries: p.m.de.vries@vu.nl